{"id":"addition-of-thalidomide-and-hydroxyurea","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Teratogenicity (thalidomide)"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Thalidomide is an immunomodulatory agent that inhibits tumor necrosis factor-alpha production and angiogenesis while promoting T-cell proliferation and cereblon binding. Hydroxyurea increases fetal hemoglobin (HbF) levels and reduces sickling through ribonucleotide reductase inhibition. In combination, these agents target multiple pathways relevant to hematologic malignancies and severe hemolytic anemias.","oneSentence":"Thalidomide and hydroxyurea work synergistically to inhibit angiogenesis, promote apoptosis of abnormal cells, and enhance fetal hemoglobin production while reducing sickling and hemolysis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:20:42.562Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sickle cell disease (Phase 2)"},{"name":"Multiple myeloma or other hematologic malignancies (investigational)"}]},"trialDetails":[{"nctId":"NCT07292259","phase":"PHASE2","title":"Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia","status":"RECRUITING","sponsor":"Pakistan Blood and Marrow Transplant (PBMT) Group","startDate":"2024-01-01","conditions":"Transfusion Dependent Beta Thalassemia","enrollment":150},{"nctId":"NCT04576156","phase":"PHASE3","title":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geron Corporation","startDate":"2021-04-12","conditions":"Myelofibrosis","enrollment":327},{"nctId":"NCT06490601","phase":"PHASE2","title":"Long Term Beta Thalassemia Treatment: Findings From The Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2022-04-01","conditions":"Fetal Hemoglobin, Beta-Thalassemia, Hemoglobinopathies","enrollment":30},{"nctId":"NCT06146478","phase":"PHASE3","title":"Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients","status":"COMPLETED","sponsor":"Blood Care Clinic","startDate":"2022-01-25","conditions":"Transfusion-dependent Beta-Thalassemia","enrollment":200},{"nctId":"NCT03651102","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia","status":"COMPLETED","sponsor":"Blood Diseases Clinic","startDate":"2018-01-01","conditions":"Thalassemia","enrollment":654}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hydrea and Thalidomide"],"phase":"phase_2","status":"active","brandName":"ADDITION OF THALIDOMIDE AND HYDROXYUREA","genericName":"ADDITION OF THALIDOMIDE AND HYDROXYUREA","companyName":"Pakistan Blood and Marrow Transplant (PBMT) Group","companyId":"pakistan-blood-and-marrow-transplant-pbmt-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Thalidomide and hydroxyurea work synergistically to inhibit angiogenesis, promote apoptosis of abnormal cells, and enhance fetal hemoglobin production while reducing sickling and hemolysis. Used for Sickle cell disease (Phase 2), Multiple myeloma or other hematologic malignancies (investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}